Ortin Laboratories Ltd - 539287 - Closure of Trading Window
The trading window for dealing in the securities of the Company will remain closed from 30th June, 2019 till 48 hours after the declaration of financial results for the quarter ended 30.06.2019 Ortin Laboratories Ltd - 539287 - Clarification sought from Ortin Laboratories Ltd
The Exchange has sought clarification from Ortin Laboratories Ltd on June 3, 2019 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. Ortin Laboratories Ltd - 539287 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report30/05/2019 3 Name of the Certifying Firm Vivek Surana & Associates 4 Name of the Certifying Individual Vivek Surana 5Membership TypeACS 6 Membership Number 24531 7 CP No. 12901 8 Whether any observations/qualification reported by the Secretarial Auditor ? Yes Ortin Laboratories Ltd - 539287 - Audited Financial Results For The Quarter And Year Ended 31.03.2019
Audited financial results for the quarter and year ended 31.03.2019 Ortin Laboratories Ltd - 539287 - Board Meeting Intimation for The Audited Financial Results For The Quarter And Year Ended 31-03-2019
Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve the audited financial results for the quarter and year ended 31-03-2019 Ortin Laboratories Ltd - 539287 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayOrtin Laboratories Ltd 2CININE749B01012 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 82479266 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: SHARVARI SWAPNIL SHINDE Designation: COMPANY SECRETARY & COMPLIANCE OFFICER EmailId: info@ortinlabsindia.com Name of the Chief Financial Officer: SATYANARAYANA RAJU BHUPATHIRAJU Designation: CFO EmailId: info@ortinlabsindia.com Date: 27/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Ortin Laboratories Ltd - 539287 - Disclosure Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Ortin Laboratories Ltd - 539287 - Compliance With SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31.03.2019
Compliance with SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the half year ended 31.03.2019 Ortin Laboratories Ltd - 539287 - Shareholding for the Period Ended March 31, 2019
Ortin Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here